Form 4: Tarsus Pharmaceuticals Director Andrew Goldberg Reports New Equity Grants and RSU Settlement

Tarsus Pharmaceuticals, Inc. Director Andrew D. Goldberg reported the acquisition of common stock from RSU settlement, new stock options, and new restricted stock units related to his service.

Summary

• Andrew D. Goldberg, a Director of Tarsus Pharmaceuticals, Inc. (TARS), reported several equity transactions.
• On June 13, 2025, he acquired 3,350 shares of common stock through the settlement of previously vested Restricted Stock Units (RSUs).
• Following this transaction, he directly beneficially owns 16,700 shares of common stock.
• On June 12, 2025, he was granted 4,540 stock options with an exercise price of $40.95.
• Also on June 12, 2025, he was granted 2,954 new Restricted Stock Units (RSUs).
• The 3,350 RSUs that settled on June 13, 2025, were originally granted on June 13, 2024, and vested on their one-year anniversary.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, including new grants of stock options and RSUs, which generally aligns director interests with shareholder value. There are no negative transactions like sales of common stock reported, only acquisitions and vesting events.

Positives

• Director Andrew D. Goldberg received new equity grants (stock options and RSUs), aligning his interests with shareholders.
• The vesting schedule for new options and RSUs encourages long-term commitment from the director, as vesting is contingent on continuous service.

Future Outlook

The vesting schedules for the newly granted stock options and Restricted Stock Units indicate a future commitment from Director Andrew D. Goldberg to Tarsus Pharmaceuticals, with vesting contingent on his continuous service through June 12, 2026.

Industry Context

This Form 4 filing reflects routine equity compensation practices for non-employee directors in the pharmaceutical industry, aiming to align director incentives with long-term shareholder value through stock options and restricted stock units.

Comparison to Industry Standards

• The equity grants to Director Andrew D. Goldberg, including stock options and Restricted Stock Units with one-year cliff vesting, are consistent with common compensation practices for non-employee directors in the biotechnology and pharmaceutical sectors.
• Such structures are designed to incentivize long-term commitment and align director interests with shareholder returns, similar to practices observed at comparable companies like Alnylam Pharmaceuticals or Sarepta Therapeutics, which also utilize equity-based compensation for their board members.

Stakeholder Impact

• Shareholders: The director's increased equity stake aligns his interests with shareholder value creation.

Next Steps

• Vesting of 4,540 stock options on June 12, 2026, subject to continuous service.
• Vesting of 2,954 Restricted Stock Units on June 12, 2026, subject to continuous service.

Key Dates

Keywords

Tarsus Pharmaceuticals, TARS, SEC Form 4, insider transaction, director compensation, stock options, restricted stock units, equity grants, beneficial ownership